<DOC>
	<DOCNO>NCT01681303</DOCNO>
	<brief_summary>Recent research work direct especial attention toward distinct group uremic retension molecule , call `` protein-bound uremic toxin '' . The prototype group uremic toxin indoxyl sulfate p-cresol . These uremic toxin promote production free radical impair antioxidant system exerts direct toxicity different cell organ , include mesangial , tubular , endothelial cell osteoblast . Accumulation protein bind uremic toxin result glomerular sclerosis interstitial fibrosis kidney uremic rat confer skeletal resistance parthyroid hormone uremic patient . In hemodialysis , high serum p-cresol level associate high cardiovascular mortality . AST-120 ( Kremezin ) carbonate oral absorbent extensively use Japan Korea . It superior adsorption ability certain small-molecular weight organic compound know accumulate patient CKD . In uremic rat CKD patient , oral administration AST-120 decrease elevate pretreatment level serum indoxyl sulfate . In Japan , report AST-120 suppress increase serum creatinine level , prevent proteinuria , improve uremic symptom , , consequently , lead postponement dialysis therapy . Value AST-120 outcome late-stage CKD patient still unknown . We hypothesize AST-120 reduction level indoxyl sulfate p-cresol improve morbidity- mortality CKD patient . The principal aim prospective cohort study investigate effectiveness AST-120 incidence dialysis mortality late-stage CKD patient . Determination relationship help establish new therapeutic strategy treatment late-stage CKD patient .</brief_summary>
	<brief_title>Effect An Oral Absorbent AST-120 Late-stage Chronic Kidney Disease ( CKD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>adult age &gt; 18 yearold &lt; 85 yearold eGFR CCR &lt; 60 ml/min hemoglobin &lt; 10 g/dL , ESAna√Øve , adequate iron storage ( serum ferritin &gt; 200 ng/dL transferrin saturation &gt; 20 % ) spontaneous renal improvement progression past 3 month . renal transplant recipient , liver cirrhosis , bone marrow disorder blood pressure &gt; 170/80 mmHg 3 occasion recent cardiovascular disease ( Coronary artery disease , myocardial ischemia , cerebrovascular disease peripheral artery disease ) gastrointestinal bleed past 3 month acute tubular necrosis past 3 month unwilling participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>